体外膜氧合能否改善儿童急性呼吸衰竭的生存?
该队列研究从集群随机RESTORE试验中选取严重ARDS患儿,比较ECMO支持与非ECMO支持者的结局。采用个体病例匹配(60对)时,90天住院死亡率两组均为25%(各15/60,P>0.99);采用倾向评分匹配(61对)时,ECMO支持组住院死亡率为25%(15/61),非ECMO支持组为30%(18/61)(P=0.70)。两组在任何次要结局上均无差异。结论认为,结果未证明ECMO支持患儿结局优于非ECMO支持患儿,明确答案需严谨的多中心随机对照试验。
要点
- 在严重ARDS患儿中,个体病例匹配(60对)显示ECMO支持与非ECMO支持的90天住院死亡率均为25%(各15/60,P>0.99)。
- 倾向评分匹配(61对)显示ECMO支持组住院死亡率为25%(15/61),非ECMO支持组为30%(18/61),P=0.70。
- ECMO支持与非ECMO支持患儿在任何次要结局(包括无住院天数、无呼吸机天数、出院时功能状态变化)上均无差异。
- 作者结论:结果未证明ECMO支持患儿结局优于非ECMO支持患儿,明确答案需严谨的多中心随机对照试验。
适用人群与场景
- 选自集群随机RESTORE临床试验的严重急性呼吸窘迫综合征(ARDS)患儿。
- 纳入879例(35.9%)非ECMO支持且符合匹配条件的严重ARDS患儿,与61例(2.5%)ECMO支持患儿进行匹配。
研究设计与关键结果
- 研究类型:队列研究,比较ECMO支持与非ECMO支持(配对匹配)的严重ARDS患儿;样本来自RESTORE试验的2449例患儿。
- 个体病例匹配(60对):90天住院死亡率ECMO支持组25%(15/60) vs 非ECMO支持组25%(15/60),P>0.99。
- 倾向评分匹配(61对):住院死亡率ECMO支持组25%(15/61) vs 非ECMO支持组30%(18/61),P=0.70。
- 次要结局(无住院天数、无呼吸机天数、出院时功能状态变化):ECMO支持组与非ECMO支持组之间均无差异。
证据类型、等级与局限
- 证据类型:队列研究(病例匹配及倾向评分匹配),样本来自集群随机RESTORE临床试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论:在严重ARDS患儿中,结果未证明ECMO支持患儿结局优于非ECMO支持患儿;明确答案需严谨的多中心随机对照试验。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
RATIONALE: Extracorporeal membrane oxygenation (ECMO) has supported gas exchange in children with severe respiratory failure for more than 40 years, without ECMO efficacy studies.
OBJECTIVES: To compare the mortality and functional status of children with severe acute respiratory failure supported with and without ECMO.
METHODS: This cohort study compared ECMO-supported children to pair-matched non-ECMO-supported control subjects with severe acute respiratory distress syndrome (ARDS). Both individual case matching and propensity score matching were used. The study sample was selected from children enrolled in the cluster-randomized RESTORE (Randomized Evaluation of Sedation Titration for Respiratory Failure) clinical trial. Detailed demographic and daily physiologic data were used to match patients. The primary endpoint was in-hospital mortality. Secondary outcomes included hospital-free days, ventilator-free days, and change in functional status at hospital discharge.
MEASUREMENTS AND MAIN RESULTS: Of 2,449 children in the RESTORE trial, 879 (35.9%) non-ECMO-supported patients with severe ARDS were eligible to match to 61 (2.5%) ECMO-supported children. When individual case matching was used (60 matched pairs), the in-hospital mortality rate at 90 days was 25% (15 of 60) for both the ECMO-supported and non-ECMO-supported children (P > 0.99). With propensity score matching (61 matched pairs), the ECMO-supported in-hospital mortality rate was 15 of 61 (25%), and the non-ECMO-supported hospital mortality rate was 18 of 61 (30%) (P = 0.70). There was no difference between ECMO-supported and non-ECMO-supported patients in any secondary outcomes.
CONCLUSIONS: In children with severe ARDS, our results do not demonstrate that ECMO-supported children have superior outcomes compared with non-ECMO-supported children. Definitive answers will require a rigorous multisite randomized controlled trial.
参考来源
- Barbaro RP, Xu Y, Borasino S, et al. Does Extracorporeal Membrane Oxygenation Improve Survival in Pediatric Acute Respiratory Failure? Am J Respir Crit Care Med. 2018. PMID: 29373797. doi:10.1164/rccm.201709-1893OC
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。